1. The renaming is the message
The 2023 guideline — developed by a joint expert committee convened by China’s National Expert Committee on Cardiovascular Diseases with the Chinese Society of Cardiology and allied societies, and published in the Chinese Circulation Journal — is not titled a “dyslipidemia prevention and treatment guideline.” Its committee explicitly voted to rename it a lipid management guideline, dropping “prevention and treatment” in favour of “management.”
That vocabulary change is doing real work. The 2016 edition was organised around detecting and correcting abnormal lipid values. The 2023 edition is organised around something different — cumulative lifetime exposure. It states that statins, once effective and tolerated, should be continued long term specifically to “reduce the patient’s lifetime LDL-C exposure,” and it extends its scope down to children and adolescents.
Moving from treating a number to managing a trajectory over decades changes what counts as an unmet need. If LDL-C must be controlled for life, then the risk that remains once LDL-C is controlled stops being a rounding error. It becomes the next problem to solve — and that is the door through which omega-3 enters.
2. The burden the guideline is written against
The epidemiology justifies the urgency.
- In the 2018 national survey, dyslipidemia prevalence among adults aged 18 and over reached 35.6%, higher than in 2015.
- Age-standardised prevalence of high total cholesterol (≥ 6.2 mmol/L) nearly doubled between 2015 and 2018, from 4.9% to 8.2%.
- The share of adults with LDL-C ≥ 4.1 mmol/L rose from 5.6% (2010) to 7.2% (2015) to 8.0% (2018).
- In 1980 China’s mean total cholesterol and non-HDL-C were among the world’s lowest; by 2018 they had reached or exceeded the averages of some Western countries.
- Rising population cholesterol is projected to produce roughly 9.2 million additional cardiovascular events in China between 2010 and 2030.
Against that, treatment is thin. Awareness of dyslipidemia among adults aged 35 and over was just 16.1%. In high-risk primary prevention, lipid-lowering treatment rate was 5.5%; among patients who already had ASCVD it was 14.5%, with LDL-C goal attainment of only 6.8%. In a 104,516-patient acute coronary syndrome registry across 246 hospitals, 75.1% of patients were ultra-high risk, only 6.6% were at the < 1.4 mmol/L target on admission, and 95.1% of those discharged left on statin monotherapy.
3. Where the targets now sit
LDL-C remains the primary target, with notably aggressive risk-stratified goals.
| Risk category | LDL-C target |
|---|---|
| Low risk | < 3.4 mmol/L |
| Moderate / high risk | < 2.6 mmol/L |
| Very high risk | < 1.8 mmol/L, plus ≥ 50% reduction from baseline |
| Ultra-high risk | < 1.4 mmol/L, plus ≥ 50% reduction from baseline |
The rationale is quantitative: each 1 mmol/L reduction in LDL-C is associated with a 20–23% reduction in ASCVD events. Non-HDL-C stays as the secondary target (LDL-C + 0.8 mmol/L), and the guideline notes it predicts risk better than LDL-C precisely in the populations where triglycerides are high — diabetes, metabolic syndrome, obesity. Moderate-intensity statin therapy is the recommended starting point, escalating by adding a cholesterol absorption inhibitor and/or a PCSK9 inhibitor. The guideline also recommends against HDL-C as an intervention target: not every lipid number is actionable.
4. Three places omega-3 enters — and the words that matter
The guideline defines omega-3 narrowly and clinically: fish oil preparations mainly containing EPA and/or DHA, with icosapent ethyl (IPE) defined as ethyl-esterified EPA. Three recommendations follow.
High TG, for pancreatitis prevention. When TG exceeds 5.6 mmol/L, fibrates, high-purity omega-3 fatty acids or niacin may be used to reduce pancreatitis risk (Class I, Level C).
IPE after statin, for ASCVD risk. In ASCVD patients and high-risk individuals still above TG 2.3 mmol/L after moderate-intensity statin therapy, high-dose IPE — 2 g twice daily, i.e. 4 g/day — should be considered to reduce ASCVD risk (Class IIa, Level B). Added to statins, IPE cut MACE relative risk by 25%.
High-purity omega-3 or fibrates as an alternative. In the same population, high-purity omega-3 fatty acids, or fenofibrate/bezafibrate, may be given to further reduce ASCVD risk (Class IIb, Level C).
The efficacy anchor: omega-3 at 4 g/day lowers triglycerides by roughly 20–30% when TG is 2.3–5.6 mmol/L, and by ≥ 30% when TG is ≥ 5.6 mmol/L. Combination data show fibrate plus omega-3 reducing TG by 60.8–71.3%, and omega-3 plus niacin by more than 33%.
Read those recommendations again and the commercial filter becomes visible. Every one specifies high-purity or prescription-grade material. Every one specifies a gram-scale daily dose. This is not a market for fish oil; it is a market for concentrated, characterised, pharmaceutically specified EPA and DHA.
5. The EPA / DHA evidence asymmetry
The guideline is unusually candid about a split the supplement industry tends to blur.
Outcome data are strongest for EPA-only material. REDUCE-IT (IPE) and Japan’s JELIS (EPA) both showed significant ASCVD risk reduction added to statin therapy. RESPECT-EPA, testing statin plus highly purified EPA 1.8 g/day in chronic stable coronary disease, missed its primary endpoint narrowly — P = 0.055 — but showed a statistically significant reduction in the secondary coronary event composite (P = 0.031).
For combined EPA + DHA the guideline is more reserved: a meta-analysis suggests EPA + DHA can also reduce cardiovascular events, but the magnitude of benefit is smaller than for IPE. And while different omega-3 compositions appear to lower triglycerides to a similar degree, that equivalence in TG lowering does not carry over into equivalent outcome evidence.
Two consequences follow. Formulators building outcome-positioned products will increasingly specify EPA-dominant grades. And suppliers will need the process capability to make them — which is a separation problem, not a blending problem.
6. The safety signal marketing tends to skip
The guideline records a dose-dependent consideration that sits awkwardly beside gram-scale dosing: atrial fibrillation risk correlates positively with omega-3 dose, and appears in the safety-monitoring column for statin-plus-omega-3 combinations alongside bleeding and gastrointestinal effects.
This is an argument for purity, not against omega-3. If the therapeutic effect requires 4 g/day, material that reaches specification with fewer non-target components — and a characterised impurity profile — is materially more useful than material that does not. Purity is not a marketing adjective here; it is what makes the dose tolerable and the dossier defensible.
7. The recommendation-versus-access gap
The most commercially interesting fact here may be regulatory. The FDA has already approved IPE for an ASCVD risk-reduction indication. In China, as of the 2023 guideline, that application was still under review.
So the position is this: a national guideline that names high-purity omega-3 and IPE, for a patient population whose treatment and goal-attainment rates are extremely low, in a market where the corresponding outcome indication is not yet broadly available. That is a market defined by a widening gap between what the guideline asks for and what the supply side can deliver.
8. What it means for the omega-3 supply chain
Concentration is the entry ticket. A guideline written in grams per day at “high purity” silently disqualifies low-concentration fish oil. The question is no longer whether a supplier can produce omega-3, but whether they can deliver 70–88% EPA+DHA concentrates — and single-monomer grades where EPA or DHA exceeds 85% with the counterpart held below 0.1%.
Impurity profile is the regulatory argument. For material positioned toward prescription-grade use, the impurity routes matter as much as the assay: no urea or methanol in the process, no ethyl carbamate, no cis-trans isomerisation. These are the questions a dossier asks.
Sensory quality becomes a compliance issue. At four grams a day, colour and odour stop being cosmetic. A concentrate that is nearly colourless (Gardner ≤ 2) and almost odourless is one a patient can take consistently — and consistency is the entire premise of a guideline built on lifetime exposure.
The takeaway
The 2023 guideline did not simply add omega-3 to a list. It drew a line. On one side sits wellness-positioned fish oil; on the other, high-purity EPA and DHA specified by dose, purity and outcome evidence. The line is drawn in the language of concentration percentages, impurity limits and monomer separation.
For producers, the strategic question is which side of it they can credibly stand on. For formulators, it is which grades they can source consistently enough to build both a product and a claim around.
Industry commentary on a published clinical guideline, intended for a professional non-clinical audience. Not medical advice. Recommendations, dosing and treatment decisions should be taken from the source document — China Lipid Management Guideline (2023), Chinese Circulation Journal, March 2023, Vol. 38, No. 3 — and from qualified clinicians.
